TY - JOUR A1 - Thiem, Alexander A1 - Hesbacher, Sonja A1 - Kneitz, Hermann A1 - di Primio, Teresa A1 - Heppt, Markus V. A1 - Hermanns, Heike M. A1 - Goebeler, Matthias A1 - Meierjohann, Svenja A1 - Houben, Roland A1 - Schrama, David T1 - IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression JF - Journal of Experimental & Clinical Cancer Research N2 - Background Immune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274) expression is associated with better clinical response and increased survival to anti-PD-1 therapy. Moreover, there is increasing evidence that tumor suppressor proteins are involved in immune regulation and are capable of modulating the expression of immune checkpoint proteins. Here, we determined the role of p53 protein (gene name: TP53) in the regulation of PD-L1 expression in melanoma. Methods We analyzed publicly available mRNA and protein expression data from the cancer genome/proteome atlas and performed immunohistochemistry on tumors with known TP53 status. Constitutive and IFN-ɣ-induced PD-L1 expression upon p53 knockdown in wildtype, TP53-mutated or JAK2-overexpressing melanoma cells or in cells, in which p53 was rendered transcriptionally inactive by CRISPR/Cas9, was determined by immunoblot or flow cytometry. Similarly, PD-L1 expression was investigated after overexpression of a transcriptionally-impaired p53 (L22Q, W23S) in TP53-wt or a TP53-knockout melanoma cell line. Immunoblot was applied to analyze the IFN-ɣ signaling pathway. Results For TP53-mutated tumors, an increased CD274 mRNA expression and a higher frequency of PD-L1 positivity was observed. Interestingly, positive correlations of IFNG mRNA and PD-L1 protein in both TP53-wt and -mutated samples and of p53 and PD-L1 protein suggest a non-transcriptional mode of action of p53. Indeed, cell line experiments revealed a diminished IFN-ɣ-induced PD-L1 expression upon p53 knockdown in both wildtype and TP53-mutated melanoma cells, which was not the case when p53 wildtype protein was rendered transcriptionally inactive or by ectopic expression of p53\(^{L22Q,W23S}\), a transcriptionally-impaired variant, in TP53-wt cells. Accordingly, expression of p53\(^{L22Q,W23S}\) in a TP53-knockout melanoma cell line boosted IFN-ɣ-induced PD-L1 expression. The impaired PD-L1-inducibility after p53 knockdown was associated with a reduced JAK2 expression in the cells and was almost abrogated by JAK2 overexpression. Conclusions While having only a small impact on basal PD-L1 expression, both wildtype and mutated p53 play an important positive role for IFN-ɣ-induced PD-L1 expression in melanoma cells by supporting JAK2 expression. Future studies should address, whether p53 expression levels might influence response to anti-PD-1 immunotherapy. KW - Melanoma KW - PD-L1 KW - CD274 KW - p53 KW - TP53 KW - JAK2 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201016 VL - 38 ER - TY - THES A1 - Grimm, Johannes T1 - Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma T1 - Autokrine und parakrine Effekte BRAF-Inhibitor-induzierter Seneszenz im Melanom N2 - The FDA approval of targeted therapy with BRAFV600E inhibitors like vemurafenib and dabrafenib in 2011 has been the first major breakthrough in the treatment of metastatic melanoma since almost three decades. Despite increased progression free survival and elevated overall survival rates, complete responses are scarce due to resistance development approximately six months after the initial drug treatment. It was previously shown in our group that melanoma cells under vemurafenib pressure in vitro and in vivo exhibit features of drug-induced senescence. It is known that some cell types, which undergo this cell cycle arrest, develop a so-called senescence associated secretome and it has been reported that melanoma cell lines also upregulate the expression of different factors after senescence induction. This work describes the effect of the vemurafenib-induced secretome on cells. Conditioned supernatants of vemurafenib-treated cells increased the viability of naive fibroblast and melanoma cell lines. RNA analysis of donor melanoma cells revealed elevated transcriptional levels of FGF1, MMP2 and CCL2 in the majority of tested cell lines under vemurafenib pressure, and I could confirm the secretion of functional proteins. Similar observations were also done after MEK inhibition as well as in a combined BRAF and MEK inhibitor treatment situation. Interestingly, the transcription of other FGF ligands (FGF7, FGF17) was also elevated after MEK/ERK1/2 inhibition. As FGF receptors are therapeutically relevant, I focused on the analysis of FGFR-dependent processes in response to BRAF inhibition. Recombinant FGF1 increased the survival rate of melanoma cells under vemurafenib pressure, while inhibition of the FGFR pathway diminished the viability of melanoma cells in combination with vemurafenib and blocked the stimulatory effect of vemurafenib conditioned medium. The BRAF inhibitor induced secretome is regulated by active PI3K/AKT signaling, and the joint inhibition of mTor and BRAFV600E led to decreased senescence induction and to a diminished induction of the secretome-associated genes. In parallel, combined inhibition of MEK and PI3K also drastically decreased mRNA levels of the relevant secretome components back to basal levels. In summary, I could demonstrate that BRAF inhibitor treated melanoma cell lines acquire a specific PI3K/AKT dependent secretome, which is characterized by FGF1, CCL2 and MMP2. This secretome is able to stimulate other cells such as naive melanoma cells and fibroblasts and contributes to a better survival under drug pressure. These data are therapeutically highly relevant, as they imply the usage of novel drug combinations, especially specific FGFR inhibitors, with BRAF inhibitors in the clinic. N2 - Die Zulassung der spezifischen BRAFV600E Inhibitoren Vemurafenib und Dabrafenib im Jahr 2011 war der erste wirksame Schritt nach Jahrzehnten der Stagnation in der Behandlung des metastasierenden Melanoms. Allerdings zeigte sich, dass trotz erhöhter Gesamtüberlebensrate und gestiegenem progressionsfreien Überleben komplette Remissionen selten waren. Wir konnten in vorangegangenen Versuchen zeigen, dass eine Behandlung BRAFV600E-mutierter Melanom Zelllinien mit Vemurafenib mit der Induktion von Seneszenz-assoziierten Merkmalen einhergeht. Da bekannt ist, dass seneszente Zellen, darunter auch Melanom Zellen, ein sogenanntes Sekretom ausbilden können, welches andere Zellen beeinflussen kann, war die Identifizierung und Charakterisierung von Vemurafenib-induzierten sezernierten Faktoren das Ziel meiner Arbeit. Initiale Versuche zeigten, dass konditionierter Überstand von Vemurafenib behandelten Zellen das Wachstum naiver Zelllinien erhöhen kann. Ich konnte in weiteren Versuchen zeigen, dass sich die Transkription und Expression des Cytokins CCL2, der Matrixmetalloprotease MMP2 und des Wachstumsfaktors FGF1 nach Vemurafenib Behandlung erhöht. Darüber hinaus konnte ich interessanterweise auch eine gesteigerte Transkription anderer FGF Liganden (FGF7, FGF17) feststellen, was meinen Fokus auf die Analyse von FGFR abhängigen Prozessen als Antwort auf die BRAF Inhibition gelenkt hat. Es zeigte sich, dass sich Melanomzellen mittels Zugabe von FGF1 besser gegen die Vemurafenib-induzierte MEK/ERK1/2 Hemmung behaupten können. Darüber hinaus konnte durch den Einsatz eines spezifischen FGFR Inhibitors die Viabilität von Melanomzellen unter Vemurafenib Behandlung vermindert werden. Auch der stimulierende Effekt des Vemurafenib konditionierten Überstandes konnte dadurch teilweise aufgehoben werden. Die Induktion des BRAF Inhibitor assoziierten Sekretoms ist auf einen aktiven PI3K/AKT Signalweg angewiesen. So führt eine gleichzeitige Hemmung des MEK/ERK1/2 und PI3K/AKT Signalwegs zu einer verminderten Seneszenzinduktion und einer niedrigeren Transkription der Seneszenz-assoziierten Gene. Zudem konnte ich feststellen, dass auch eine gemeinsame Hemmung von BRAF und MEK Seneszenz und das damit einhergehende Sekretom unter Beteiligung von CCL2, MMP2 und den FGFs induziert. Zusammenfassend zeigen meine Daten, dass BRAFV600E-mutierte Melanomzellen nach Vemurafenib Behandlung ein Sekretom ausbilden, welches potentiell wachstumsfördernde und matrix-modellierende Faktoren beinhaltet. Dies ist abhängig vom PI3K/AKT Signalweg und charakterisiert durch die Sekretion von FGF1, CCL2 und MMP2. Klinische Relevanz erlangen diese Erkenntnisse durch die Möglichkeit, diese Faktoren im Rahmen einer Kombinationstherapie, z.B. mit einem spezifischen FGFR Inhibitor, zu inaktivieren. KW - Melanoma KW - Inhibitor KW - Melanom Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-181161 ER - TY - THES A1 - Kleffel, Sonja Beate T1 - The role of cancer cell-expressed PD-1 in tumorigenesis and tumor immune evasion T1 - Funktionelle Charakterisierung von Tumorzell-exprimiertem PD-1 in der Karzinogenese und antitumoralen Immunabwehr N2 - Melanoma and Merkel cell carcinoma (MCC) are highly aggressive cancers of the skin that frequently escape immune recognition and acquire resistance to chemotherapeutic agents, which poses a major obstacle to successful cancer treatment. Recently, a new class of therapeutics targeting the programmed cell death-1 (PD-1) immune checkpoint receptor has shown remarkable efficacy in the treatment of both cancers. Blockade of PD-1 on T cells activates cancer-specific immune responses that can mediate tumor regression. The data presented in this Ph.D. thesis demonstrates that PD-1 is also expressed by subsets of cancer cells in melanoma and MCC. Moreover, this work identifies PD-1 as a novel tumor cell-intrinsic growth receptor, even in the absence of T cell immunity. PD-1 is expressed by tumorigenic cell subsets in melanoma patient samples and established human and murine cell lines that also co-express ABCB5, a marker of immunoregulatory tumor- initiating cells in melanoma. Consistently, melanoma-expressed PD-1 downmodulates T effector cell functions and increases the intratumoral frequency of tolerogenic myeloid- derived suppressor cells. PD-1 inhibition on melanoma cells by RNA interference, blocking antibodies, or mutagenesis of melanoma-PD-1 signaling motifs suppresses tumor growth in immunocompetent, immunocompromised, and PD-1-deficient tumor graft recipient mice. Conversely, melanoma-specific PD-1 overexpression enhances tumorigenicity, including in mice lacking adaptive immunity. Engagement of melanoma- PD-1 by its ligand PD-L1 promotes tumor growth, whereas melanoma-PD-L1 inhibition or knockout of host-PD-L1 attenuates growth of PD-1-positive melanomas. Mechanistically, the melanoma-PD-1 receptor activates mTOR signaling mediators, including ribosomal protein S6. In a proof-of-concept study, tumoral expression of phospho-S6 in pretreatment tumor biopsies correlated with clinical responses to anti-PD-1 therapy in melanoma patients. In MCC, PD-1 is similarly co-expressed by ABCB5+ cancer cell subsets in clinical tumor specimens and established human cell lines. ABCB5 renders MCC cells resistant to the standard-of-care chemotherapeutic agents, carboplatin and etoposide. Antibody-mediated ABCB5 blockade reverses chemotherapy resistance and inhibits tumor xenograft growth by enhancing chemotherapy-induced tumor cell killing. Furthermore, engagement of MCC-expressed PD-1 by its ligands, PD-L1 and PD-L2, promotes proliferation and activates MCC-intrinsic mTOR signaling. Consistently, antibody- mediated PD-1 blockade inhibits MCC tumor xenograft growth and phosphorylation of mTOR effectors in immunocompromised mice. In summary, these findings identify cancer cell-intrinsic functions of the PD-1 pathway in tumorigenesis and suggest that blocking melanoma- and MCC-expressed PD-1 might contribute to the striking clinical efficacy of anti-PD-1 therapy. Additionally, these results establish ABCB5 as a previously unrecognized chemoresistance mechanism in MCC. N2 - Das Melanom und das Merkelzellkarzinom (MZK) sind auttumoren neuroendokrinen Ursprungs, die sich durch ein besonders aggressives Wachstum auszeichnen. Melanome und MZK entgehen häufig der antitumoralen Immunabwehr und erwerben Resistenzen gegen Chemotherapeutika, was eine erfolgreiche Behandlung der betroffenen Patienten erschwert. In klinischen Studien hat eine neue Klasse von therapeutischen Antikörpern, die den Immun-Checkpoint Rezeptor PD-1 (Programmed Cell Death-1) inhibieren, hohe Ansprechraten und dauerhafte Remissionen bei Melanom- und MZK-Patienten erzielt. Die Blockade des PD-1 Rezeptors auf T-Zellen reaktiviert autologe Immunreaktionen gegen Tumorzellen, die zur Reduktion des Tumors führen können. Die vorgelegte Dissertation zeigt, dass Subpopulationen von Melanom- und MZK-Zellen PD-1 exprimieren, und dass die Aktivierung von Tumorzell-intrinsischem PD-1 einen pro-tumorigenen Mechanismus darstellt, einschliesslich in T-Zell-defizienten Mäusen. In Biopsien von Melanom-Patienten, sowie in humanen und murinen Melanom-Zelllinien wird PD-1 präferentiell von tumorigenen, immunregulatorischen, ABCB5+ Melanom-Stammzellen exprimiert. PD-1+ Melanomzellen hemmen die Aktivität von Effektor-T-Zellen und erhöhen die Anzahl der tolerogenen myeloiden Suppressorzellen im Tumor. Die Inhibierung des PD-1 Rezeptors auf Melanomzellen durch RNA-Interferenz, blockierende Antikörper oder Mutagenese der intrazellulären Signalmotive des PD-1 Proteins unterdrückt das Melanom-Wachstum in immunkompetenten, immunsupprimierten und PD-1-defizienten Mäusen. Umgekehrt führt die Melanom-spezifische Überexpression von PD-1 zu einem signifikant erhöhtem Tumorwachstum, sogar in immunsupprimierten Mäusen. Die Aktivierung des PD-1 Rezeptors auf Melanomzellen durch die Bindung seines Liganden, PD-L1, fördert das Tumorwachstum, während das protumorigene Potential von PD-1-positiven Melanomzellen durch die Inhibierung von PD-L1 auf Melanomzellen, sowie in PD-L1-defizienten Mäusen, gehemmt wird. In Melanomzellen aktiviert der PD-1 Rezeptor den mTOR Signaltransduktionsweg, einschließlich des Effektormoleküls ribosomales Protein S6. In einer Teststudie korrelierte die Expression des Phospho-S6 Proteins in Melanomzellen aus Biopsien, die vor Gabe der Immuntherapie entnommen wurden, mit den Ansprechraten der Melanom Patienten auf die Behandlung mit PD-1-Antikörpern. Auch in Biopsien von MZK-Patienten und in etablierten humanen MZK-Zelllinien wird PD-1 präferentiell von ABCB5+ Subpopulationen exprimiert. Im MZK vermittelt der ABCB5-Membrantransporter Resistenzen gegenüber den Zytostatika Carboplatin und Etoposid. Die Antikörper-vermittelte Blockade des ABCB5-Transporters sensibilisiert MZK-Zellen für die Carboplatin- und Etoposid-vermittelte Apoptose, was zu einer signifikanten Reduktion des experimentellen Tumorwachstums führt. Ähnlich wie im Melanom fördert die Bindung des PD-1 Rezeptors auf MZK Zellen durch seine Liganden, PD-L1 und PD-L2, deren Proliferation und die intrazelluläre Aktivierung der mTORSignalkaskade. Entsprechend führt die antikörper-vermittelte Blockade von PD-1 zur Inhibierung des MZK-Tumorwachstums in immunsupprimierten Mäusen und zu einer reduzierten Phosphorylierung von mTOR Effektormolekülen. Zusammenfassend konnte in der vorliegenden Dissertation gezeigt werden, dass Subpopulationen von Melanom- und MZK-Zellen PD-1 exprimieren, und dass Tumorzell-intrinsische PD-1-Funktionen das Krebswachstum fördern. Diese Ergebnisse deuten darauf hin, dass die Blockade des PD-1-Rezeptors auf Tumorzellen zu der klinischen Wirksamkeit der anti-PD-1 Therapie beitragen könnte. Darüber hinaus konnte ABCB5 als neuer Chemoresistenz-Mechanismus in MZK identifiziert werden. KW - Melanom KW - Merkelzellkarzinom KW - Cancer KW - Melanoma KW - Merkel cell carcinoma KW - Cancer immunotherapy KW - Chemotherapeutic resistance Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-151205 ER - TY - JOUR A1 - Teutschbein, Janka A1 - Haydn, Johannes M. A1 - Samans, Birgit A1 - Krause, Michael A1 - Eilers, Martin A1 - Schartl, Manfred A1 - Meierjohann, Svenja T1 - Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins N2 - Background: Melanoma is an aggressive tumor with increasing incidence. To develop accurate prognostic markers and targeted therapies, changes leading to malignant transformation of melanocytes need to be understood. In the Xiphophorus melanoma model system, a mutated version of the EGF receptor Xmrk (Xiphophorus melanoma receptor kinase) triggers melanomagenesis. Cellular events downstream of Xmrk, such as the activation of Akt, Ras, B-Raf or Stat5, were also shown to play a role in human melanomagenesis. This makes the elucidation of Xmrk downstream targets a useful method for identifying processes involved in melanoma formation. Methods: Here, we analyzed Xmrk-induced gene expression using a microarray approach. Several highly expressed genes were confirmed by realtime PCR, and pathways responsible for their induction were revealed using small molecule inhibitors. The expression of these genes was also monitored in human melanoma cell lines, and the target gene FOSL1 was knocked down by siRNA. Proliferation and migration of siRNA-treated melanoma cell lines were then investigated. Results: Genes with the strongest upregulation after receptor activation were FOS-like antigen 1 (Fosl1), early growth response 1 (Egr1), osteopontin (Opn), insulin-like growth factor binding protein 3 (Igfbp3), dual-specificity phosphatase 4 (Dusp4), and tumor-associated antigen L6 (Taal6). Interestingly, most genes were blocked in presence of a SRC kinase inhibitor. Importantly, we found that FOSL1, OPN, IGFBP3, DUSP4, and TAAL6 also exhibited increased expression levels in human melanoma cell lines compared to human melanocytes. Knockdown of FOSL1 in human melanoma cell lines reduced their proliferation and migration. Conclusion: Altogether, the data show that the receptor tyrosine kinase Xmrk is a useful tool in the identification of target genes that are commonly expressed in Xmrk-transgenic melanocytes and melanoma cell lines. The identified molecules constitute new possible molecular players in melanoma development. Specifically, a role of FOSL1 in melanomagenic processes is demonstrated. These data are the basis for future detailed analyses of the investigated target genes. KW - Melanoma Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-67900 ER -